Stem definition | Drug id | CAS RN |
---|---|---|
prostaglandins | 913 | 363-24-6 |
Dose | Unit | Route |
---|---|---|
0.50 | mg | O |
0.50 | mg | V |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 4.05 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 23, 1977 | FDA | PHARMACIA AND UPJOHN | |
Jan. 23, 2020 | PMDA | Ferring Pharmaceuticals Co., Ltd. |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Uterine hyperstimulation | 278.80 | 54.84 | 30 | 832 | 26 | 46685174 |
Exposure during pregnancy | 217.06 | 54.84 | 79 | 783 | 108133 | 46577067 |
Caesarean section | 196.22 | 54.84 | 48 | 814 | 16555 | 46668645 |
Uterine hypertonus | 182.55 | 54.84 | 23 | 839 | 143 | 46685057 |
Uterine rupture | 118.77 | 54.84 | 20 | 842 | 1044 | 46684156 |
Uterine tachysystole | 118.37 | 54.84 | 13 | 849 | 16 | 46685184 |
Postpartum haemorrhage | 95.55 | 54.84 | 18 | 844 | 1779 | 46683421 |
Meconium in amniotic fluid | 94.28 | 54.84 | 13 | 849 | 172 | 46685028 |
Premature separation of placenta | 89.93 | 54.84 | 17 | 845 | 1711 | 46683489 |
Disseminated intravascular coagulation | 86.68 | 54.84 | 26 | 836 | 18979 | 46666221 |
Anaphylactoid syndrome of pregnancy | 75.95 | 54.84 | 9 | 853 | 30 | 46685170 |
Maternal exposure during pregnancy | 66.69 | 54.84 | 34 | 828 | 102515 | 46582685 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|
Source | Code | Description |
---|---|---|
ATC | G02AD02 | GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS UTEROTONICS Prostaglandins |
FDA CS | M0017805 | Prostaglandins |
FDA EPC | N0000175454 | Prostaglandin Analog |
CHEBI has role | CHEBI:36063 | oxytocic |
CHEBI has role | CHEBI:75771 | mus musculus metabolite |
CHEBI has role | CHEBI:77746 | h. sapiens metabolites |
MeSH PA | D010120 | Oxytocics |
MeSH PA | D012102 | Reproductive Control Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Incomplete miscarriage | indication | 156072005 | |
Induction of labor | indication | 236958009 | |
Cervical ripening procedure | indication | 236959001 | |
Pregnancy with abortive outcome | indication | 363681007 | |
Hydatidiform mole, benign | indication | 417044008 | |
Ocular hypertension | contraindication | 4210003 | DOID:9282 |
Multiple pregnancy | contraindication | 16356006 | |
Grand multipara | contraindication | 18656007 | |
Disorder of lung | contraindication | 19829001 | DOID:850 |
Glaucoma | contraindication | 23986001 | DOID:1686 |
Disproportion between fetus and pelvis | contraindication | 25749005 | |
Genital herpes simplex | contraindication | 33839006 | DOID:8704 |
Placenta previa | contraindication | 36813001 | DOID:11060 |
Inflammation of cervix | contraindication | 37610005 | DOID:2568 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Low blood pressure | contraindication | 45007003 | |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Disseminated intravascular coagulation | contraindication | 67406007 | DOID:11247 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Stenosis of cervix | contraindication | 83536006 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Uterine leiomyoma | contraindication | 95315005 | DOID:13223 |
Female genital tract infection | contraindication | 125585007 | |
Seizure disorder | contraindication | 128613002 | |
Fetal distress | contraindication | 130955003 | |
Spontaneous rupture of membranes | contraindication | 169734005 | |
Asthma | contraindication | 195967001 | DOID:2841 |
Deliveries by cesarean | contraindication | 200144004 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Anemia | contraindication | 271737000 | DOID:2355 |
Abnormal uterine bleeding unrelated to menstrual cycle | contraindication | 312984006 | |
Endocervical Lesions | contraindication | ||
Uterine Hypertonic Patterns | contraindication | ||
Gynecological Surgery | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.79 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Prostaglandin E2 receptor EP3 subtype | GPCR | AGONIST | Ki | 9.48 | CHEMBL | CHEMBL | |||
Prostaglandin E2 receptor EP4 subtype | GPCR | AGONIST | Ki | 9.77 | CHEMBL | CHEMBL | |||
Prostaglandin E2 receptor EP1 subtype | GPCR | AGONIST | Ki | 8.04 | CHEMBL | CHEMBL | |||
Prostaglandin E2 receptor EP2 subtype | GPCR | AGONIST | Ki | 8.77 | CHEMBL | CHEMBL | |||
Prostacyclin receptor | GPCR | IC50 | 6.59 | CHEMBL | |||||
Cation channel sperm-associated protein 4 | Ion channel | ACTIVATOR | EC50 | 6.30 | IUPHAR | ||||
Cation channel sperm-associated protein 3 | Ion channel | ACTIVATOR | EC50 | 6.30 | IUPHAR | ||||
Cation channel sperm-associated protein 1 | Ion channel | ACTIVATOR | EC50 | 6.30 | IUPHAR | ||||
Cation channel sperm-associated protein 2 | Ion channel | ACTIVATOR | EC50 | 6.30 | IUPHAR | ||||
Prostaglandin D2 receptor | GPCR | AGONIST | Ki | 7 | IUPHAR | ||||
Prostaglandin F2-alpha receptor | GPCR | AGONIST | Ki | 6.90 | IUPHAR | ||||
Prostaglandin D2 receptor 2 | GPCR | AGONIST | Ki | 5.30 | IUPHAR | ||||
Thromboxane A2 receptor | GPCR | AGONIST | Ki | 4.50 | IUPHAR | ||||
Solute carrier family 22 member 6 | Transporter | Ki | 5.47 | CHEMBL | |||||
Solute carrier family 22 member 20 | Transporter | Ki | 4.74 | CHEMBL | |||||
Prostaglandin E2 receptor EP2 subtype | GPCR | Ki | 7.66 | CHEMBL | |||||
Prostaglandin E2 receptor EP1 subtype | GPCR | Ki | 8.22 | CHEMBL | |||||
Prostaglandin E2 receptor EP3 subtype | GPCR | Ki | 8.30 | CHEMBL | |||||
Prostaglandin E2 receptor EP4 subtype | GPCR | Ki | 8.51 | CHEMBL | |||||
Prostaglandin E2 receptor EP2 subtype | GPCR | IC50 | 8.28 | CHEMBL | |||||
Prostaglandin E2 receptor EP4 subtype | GPCR | IC50 | 8.68 | CHEMBL | |||||
Prostaglandin E2 receptor EP3 subtype | Unclassified | AGONIST | EC50 | 9.39 | IUPHAR | ||||
Prostaglandin F2-alpha receptor | GPCR | AGONIST | Ki | 7 | IUPHAR | ||||
Prostaglandin E2 receptor EP1 subtype | Unclassified | AGONIST | Ki | 7.70 | IUPHAR | ||||
Prostaglandin D2 receptor 2 | Unclassified | AGONIST | Ki | 5.50 | IUPHAR |
ID | Source |
---|---|
4018093 | VUID |
N0000146431 | NUI |
D00079 | KEGG_DRUG |
4018093 | VANDF |
C0012472 | UMLSCUI |
CHEBI:15551 | CHEBI |
P2E | PDB_CHEM_ID |
CHEMBL548 | ChEMBL_ID |
DB00917 | DRUGBANK_ID |
D015232 | MESH_DESCRIPTOR_UI |
5280360 | PUBCHEM_CID |
3075 | INN_ID |
K7Q1JQR04M | UNII |
3478 | RXNORM |
4609 | MMSL |
001309 | NDDF |
387245009 | SNOMEDCT_US |
44798001 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Prostin E2 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0827 | SUPPOSITORY | 20 mg | VAGINULLL | NDA | 20 sections |
Prepidil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-3359 | GEL | 0.50 mg | VAGINULLL | NDA | 20 sections |
CERVIDIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55566-2800 | INSERT | 10 mg | VAGINULLL | NDA | 26 sections |